Rubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of Directors
July 14 2022 - 8:00AM
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage
biopharmaceutical company that is biologically engineering red
blood cells to create an entirely new class of cellular medicines
called Red Cell Therapeutics™ for the treatment of cancer and
autoimmune diseases, today announced the appointment of Susanne
Schaffert, Ph.D., to its board of directors. Dr. Schaffert brings
more than 25 years of experience across clinical development,
marketing and sales, finance and commercialization in the global
pharmaceutical and biotechnology industries, with a focus on
oncology, immuno-oncology and cell therapy. Dr. Schaffert most
recently served as President of Novartis Oncology. Also, today,
Rubius announced that Anne Prener, M.D., Ph.D., is stepping down
from her role on the board of directors, effective today.
“Susanne’s deep knowledge in oncology drug development and
commercialization will be instrumental as we continue to advance
our oncology pipeline of Red Cell Therapeutics™, including RTX-240
and RTX-224 for the treatment of solid tumors. I am thrilled to
welcome Susanne to the Rubius board of directors,” said Pablo J.
Cagnoni, M.D., president and chief executive officer of Rubius
Therapeutics. “We’d also like to thank Anne for her many
contributions since joining the board in 2019, including her
counsel as we transitioned from a discovery-stage organization to
the clinical-stage company that we are today.”
“Rubius Therapeutics has advanced an entirely new class of
medicines and has made remarkable progress across its broad
clinical pipeline of cancer therapeutics and preclinical autoimmune
program, all supported by the proprietary RED PLATFORM® and
fully-owned manufacturing capabilities,” said Dr. Schaffert. “I
look forward to working closely with the Rubius management team and
the rest of the board as we move into later-stage development and
advance the company’s mission of bringing potentially life-changing
cellular therapies to patients with cancer and autoimmune
diseases.”
Dr. Schaffert spent 27 years at Novartis, most recently as
President of Novartis Oncology. Before that, she spent six years in
Novartis’ Oncology Business as a member of the Global Novartis
Oncology Leadership Team, including as Region Head, Novartis
Oncology Europe, where she successfully launched and marketed key
products in lung, breast and renal cancer as well as hematology.
She also served as President and Chair of Accelerated Advanced
Applications (AAA), launching Lutathera®, a radioligand therapy for
the treatment of certain cancers, in the U.S. and E.U. Also during
her tenure in Novartis’ Oncology Business, she was instrumental in
the GSK Oncology integration. From 2010-2013, Dr. Schaffert was
Head of Investor Relations, and before that, she served as Global
Franchise Head for Immunology and Transplantation. Dr. Schaffert
first joined Novartis Germany in 1995 and held a series of
positions in Sales and Marketing with increasing responsibilities
in both national and global functions. Dr. Schaffert holds a Ph.D.
with honors in Organic Chemistry and an M.Sc. in Chemistry, both
from the University of Erlangen (Germany).
About Rubius TherapeuticsRubius Therapeutics is
a clinical-stage biopharmaceutical company developing a new class
of medicines called Red Cell Therapeutics™. The Company’s
proprietary RED PLATFORM® was designed to biologically engineer and
culture Red Cell Therapeutics™ that are selective, potent and
off-the-shelf allogeneic cellular therapies for the potential
treatment of several diseases across multiple therapeutic areas.
Rubius’ initial focus is to advance RCT™ product candidates for the
treatment of cancer and autoimmune diseases by leveraging two
distinct therapeutic modalities — potent cell-cell interaction and
tolerance induction. Rubius Therapeutics was recently named
among the 2021 Top Places to Work in Massachusetts by the Boston
Globe, and its manufacturing site was recently
named 2022 Best Places to Work in Rhode Island by
Providence Business News. For more information, visit
www.rubiustx.com, follow us on Twitter or LinkedIn or like us on
Facebook.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended,
including, without limitation, statements regarding Rubius’ plans,
including plans to advance the Red Cell Therapeutics™ pipeline,
later-stage development plans and plans to advance the company’s
mission. The words “may,” “will,” “could,” “would,” “should,”
“expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,”
“predict,” “project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release are based on management’s current expectations and beliefs
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, those risks and uncertainties related to the
development of our Red Cell Therapeutic product candidates and
their therapeutic potential, our ability to execute on our plans
and expectations, our analyses of clinical and preclinical data and
other risks identified in our filings with the U.S. Securities and
Exchange Commission (SEC), including our Annual Report on Form 10-K
for the year ended December 31, 2021 and subsequent filings with
the SEC, including our Quarterly Report on Form 10-Q for the
quarter-ended March 31, 2022, and risks and uncertainties related
to the severity and duration of the impact of COVID-19 on our
business and operations. We caution you not to place undue reliance
on any forward-looking statements, which speak only as of the date
they are made. We disclaim any obligation to publicly update or
revise any such statements to reflect any change in expectations or
in events, conditions or circumstances on which any such statements
may be based, or that may affect the likelihood that actual results
will differ from those set forth in the forward-looking statements.
Any forward-looking statements contained in this press release
represent our views only as of the date hereof and should not be
relied upon as representing its views as of any subsequent
date.
Contacts:
Rubius
TherapeuticsInvestorsLori Murray, Chief
Corporate Affairs Officer lori.murray@rubiustx.com
Media Marissa Hanify, Director, Corporate
Communicationsmarissa.hanify@rubiustx.com
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Jul 2023 to Jul 2024